Core Viewpoint - Aligos Therapeutics, Inc. has announced that eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, highlighting its focus on innovative therapies for liver and viral diseases [1]. Group 1: Abstracts on Chronic Hepatitis B Virus (HBV) - Abstract 861 discusses the monotherapy with the novel capsid assembly modulator ALG-000184, showing profound and sustained HBV DNA suppression in untreated subjects over 96 weeks [2]. - Abstract 856 presents the safety and antiviral effect of oral daily 300 mg ALG-000184 in combination with Entecavir for untreated HBeAg-positive subjects, also over 96 weeks [3]. - Abstract 1924 reveals a high barrier of resistance to ALG-000184 based on viral kinetics and sequence analysis from a phase I monotherapy study [3]. Group 2: Abstracts on Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Abstract 302 highlights that ALG-055009, a novel thyroid hormone receptor beta agonist, significantly reduces atherogenic lipids/lipoproteins in patients with presumed MASH in the Phase 2a HERALD study [4]. - Abstract 2185 indicates robust reductions in liver fat at Week 12 across subgroups, including GLP-1 receptor agonist users in non-cirrhotic MASH patients [4]. - Abstract 2152 discusses population pharmacokinetic/pharmacodynamic modeling of ALG-055009, showing a statistically significant correlation between exposure and key efficacy endpoints [5]. Group 3: Preclinical Research - Abstract 2105 presents next-generation hepatitis B virus antisense oligonucleotides with significantly improved properties compared to current clinical candidates [6]. Company Overview - Aligos Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing best-in-class therapies for liver and viral diseases, leveraging its R&D expertise to address high unmet medical needs [6].